In pancreas, lipoprotein disorder induces interleukin-33 (IL-33) expression and release in pancreatic stellate cell (PSC), which strongly induced pancreatic ILC2s to trigger a type 2 immune response accompanied by the activation of PSCs, eventually leading to fibrosis during pancreatitis (52). This evidence concerns the gene IL33 and metabolic disease.